The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems?
- Registration Number
- NCT00988663
- Lead Sponsor
- Jerrry L Lewis
- Brief Summary
The purpose of this study is to determine whether memantine will enhance the therapeutic of effect on depression and prevent memory and other cognitive problems caused by ECT.
- Detailed Description
Patients will be assigned randomly either to a treatment group or a placebo groups. All patients in both groups will be receiving standard ECT. The treatment group will receive memantine. All patients will be given a battery of cognitive tests and test of depression before ECT treatments start, after the 6th ECT treatment and after the completions of ECT. An analysis will be performed to see if memantine causes any impact on the response to ECT and prevents memory and cognitive impairment.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Meets criteria for Major Depressive disorder
Exclusion Criteria
- Neurological disease
- Mental retardation
- Seizure disorder
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description placebo Placebo 25 patients receiving ECT will will receive placebo Memantine arm memantine Patient receiving ECT and Memantine placebo memantine 25 patients receiving ECT will will receive placebo
- Primary Outcome Measures
Name Time Method Assessment of whether Memantine protects memory and cognitive impairment caused by ECT. 6 to 8 weeks
- Secondary Outcome Measures
Name Time Method Whether memantine will improve response of Depression to Electroconvulsive therapy. 6-8 weeks
Trial Locations
- Locations (1)
University of Iowa hosptitals and clinic
🇺🇸Iowa City, Iowa, United States